Phendimetrazine Tartrate is an oral, indirect-acting, nonamphetamine sympathomimetic amine. It is used as an anoretic agent for short-term (8 to 12 weeks) adjunct in the treatment of exogenous obesity. The pharmacologic effects of phendimetrazine are similar to amphetamines. Phendimetrazine is only indicated for use as monotherapy. This drug was approved by the FDA in 1961.

Phendimetrazine tartrate is a weight loss medication, which is chemically related to amphetamines and is commonly prescribed for the treatment of obesity. Essentially an appetite suppressant, phendimetrazine tartrate is categorized as a Schedule III drug under the Convention on Psychotropic Substances and the Uniform Controlled Substances Act of 1970.

After being developed in Germany in 1954, phendimetrazine tartrate was quickly recognized for its efficacy and potential benefits. By the 1960s it had met the approval criteria of the United States Food and Drug Administration (FDA), passing its safety and effectiveness tests as an approved formula for weight loss and in the mid-90s its popularity increased after the FDA banned the diet drug Ephedra for its dangerous and potentially fatal side effects.

The latest diet pill rankings list phendimetrazine tartrate as the second most popular appetite suppressant formula in America and it is considered to be an effective and safe weight control aid when taken as directed.